Therapeutic Solutions International Announces Reduction of COVID-19 Associated Cognitive Decline by QuadraMune® Nutraceutical in Animal Model

Rhea-AI Summary

Therapeutic Solutions International has filed a new patent indicating that QuadraMune may reduce cognitive decline linked to COVID-19, based on studies conducted on mice. The experiments demonstrated a significant preservation of cognitive activity and reduced neural inflammation in mice treated with various doses of QuadraMune. This nutraceutical aims to address the long-term brain impacts of COVID-19, as highlighted by its potential anti-inflammatory and neuroregenerative effects. CEO Timothy Dixon emphasized the urgent need for effective treatments given the worsening understanding of COVID-19's aftermath.

Positive

• New patent filed for QuadraMune indicating potential to reduce cognitive decline related to COVID-19.
• Significant preservation of cognitive activity noted in mice treated with QuadraMune.
• Reduction of microglial activation suggests decreased neural inflammation.
• QuadraMune may provide a nutraceutical approach to mitigate COVID-19's long-term brain effects.

Negative

• None.

New Data Suggests Possible Efficacy of QuadraMune® in Treatment of COVID-19 “Brain Fog”

OCEANSIDE, Calif.--(BUSINESS WIRE)-- Therapeutic Solutions International announced today filing of a new patent covering data demonstrating QuadraMune administration reduces cognitive decline caused by administration of COVID-19 spike protein in mice.

In a series of experiments, mice were treated with artificially generated spike protein on a daily basis for 7 days in order to mimic infection with SARS-CoV-2, the virus responsible for COVID-19 disease. One group of mice received saline and two groups received a low and high dose of QuadraMune, a fourth group of mice received no treatment. Significant dose dependent preservation of cognitive activity was observed in mice receiving QuadraMune. Additionally, reduction of microglial activation, a sign of neural inflammation was reported.

QuadraMune is an immune modulating nutraceutical whose use in treatment of COVID-19 is covered by issued US Patent #11,229,674.

“The more we learn about COVID-19 brain after-effects, the more we see a consistent pattern of inflammatory cytokines and inflammatory cells eliciting changes that cause chronic brain degeneration,” said Dr. Thomas Ichim, Board Member of Therapeutic Solutions International and Co-Inventor of the patent. “We are enthusiastic about the current data, which shows preservation of brain function and reduction of inflammation. This data suggests the possibility of offering a nutraceutical approach to COVID-19 patients to protect their brains.”

COVID-19 associated brain changes have been shown to cause severe damage in certain individuals. In one recent peer reviewed study, COVID-19 brain pathology was shown to be similar to Alzheimer’s Disease¹.

“We are only now beginning to see the long-term consequences of COVID-19 infection. We believe that the potent anti-inflammatory and neuroregenerative effects of QuadraMune may be particularly useful in leveraging the body’s own mechanisms to mediate post-infection healing,” said Timothy Dixon, President and CEO of the Company.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Alzheimer's‐like signaling in brains of COVID‐19 patients - Reiken - - Alzheimer's & Dementia - Wiley Online Library

View source version on businesswire.com: https://www.businesswire.com/news/home/20220207005474/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International

FAQ

What is the new patent about filed by Therapeutic Solutions International regarding TSOI?

The new patent covers data demonstrating that QuadraMune may reduce cognitive decline caused by COVID-19 spike protein, based on studies in mice.

What were the results of the QuadraMune study mentioned in the TSOI press release?

The study showed significant preservation of cognitive activity and reduced microglial activation in mice treated with QuadraMune.

What are the implications of TSOI's findings on COVID-19 brain fog?

The findings suggest that QuadraMune's anti-inflammatory and neuroregenerative properties could help protect brain function in COVID-19 patients.